[{"id":"68f3baae-dc4f-43a6-80f0-573ab27bebb5","acronym":"ViPOR","url":"https://clinicaltrials.gov/study/NCT03223610","created_at":"2021-01-18T15:54:35.735Z","updated_at":"2025-02-25T13:39:32.188Z","phase":"Phase 1/2","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT03223610 - ViPOR","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone"],"overall_status":"Recruiting","enrollment":" Enrollment 145","initiation":"Initiation: 02/09/2018","start_date":" 02/09/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"e2ff7fb5-f1de-4b7f-9fd4-438675875b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02160015","created_at":"2021-01-18T10:03:19.018Z","updated_at":"2025-02-25T13:52:04.076Z","phase":"Phase 1","brief_title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02160015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-20"},{"id":"113cfda4-7d09-419b-a619-1fc822fa3cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03088878","created_at":"2021-01-18T15:13:07.925Z","updated_at":"2025-02-25T15:17:25.790Z","phase":"Phase 1/2","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03088878","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/03/2018","start_date":" 01/03/2018","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2025-02-12"},{"id":"8e3b627a-4aef-4d49-a1cb-f09137cdb6c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06536049","created_at":"2025-02-25T15:21:55.068Z","updated_at":"2025-02-25T15:21:55.068Z","phase":"Phase 1/2","brief_title":"Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT06536049","lead_sponsor":"Yazeed Sawalha","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Epkinly (epcoritamab-bysp)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/31/2025","start_date":" 03/31/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"825e707d-d24d-4a05-b786-1228f5cc02ad","acronym":"Window-2","url":"https://clinicaltrials.gov/study/NCT03710772","created_at":"2021-01-18T18:11:30.804Z","updated_at":"2025-02-25T15:34:12.058Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT03710772 - Window-2","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • CD20 • NSD2","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • CD20 • NSD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/22/2025","primary_completion_date":" 05/22/2025","study_txt":" Completion: 05/22/2025","study_completion_date":" 05/22/2025","last_update_posted":"2025-02-11"},{"id":"a65eaf0b-f986-4662-a858-795fc0730939","acronym":"","url":"https://clinicaltrials.gov/study/NCT04273139","created_at":"2021-01-18T20:45:24.651Z","updated_at":"2025-02-25T15:43:52.361Z","phase":"Phase 2","brief_title":"Ibrutinib + Venetoclax in Untreated WM","source_id_and_acronym":"NCT04273139","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2 • MYD88","pipe":" | ","alterations":" MYD88 mutation","tags":["BCL2 • MYD88"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYD88 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/09/2020","start_date":" 07/09/2020","primary_txt":" Primary completion: 06/06/2022","primary_completion_date":" 06/06/2022","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-11"},{"id":"256f83da-7b60-4240-9f0a-ab88796e2617","acronym":"","url":"https://clinicaltrials.gov/study/NCT06649812","created_at":"2025-02-25T15:37:38.396Z","updated_at":"2025-02-25T15:37:38.396Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","source_id_and_acronym":"NCT06649812","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 02/28/2025","start_date":" 02/28/2025","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2025-02-10"},{"id":"53b3407a-20b5-4273-98e0-b8684d9dff01","acronym":"","url":"https://clinicaltrials.gov/study/NCT01829568","created_at":"2021-01-18T08:08:01.489Z","updated_at":"2025-02-25T14:34:07.166Z","phase":"Phase 1","brief_title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","source_id_and_acronym":"NCT01829568","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/26/2013","start_date":" 06/26/2013","primary_txt":" Primary completion: 05/11/2015","primary_completion_date":" 05/11/2015","study_txt":" Completion: 01/24/2026","study_completion_date":" 01/24/2026","last_update_posted":"2025-02-10"},{"id":"6d960e71-ed2a-4ebb-b9a5-92e7b593b1dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02629809","created_at":"2021-01-18T12:47:12.967Z","updated_at":"2025-02-25T15:25:24.207Z","phase":"Phase 2","brief_title":"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT02629809","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-10"},{"id":"7aa05467-0129-42a5-a27e-e92acdec8860","acronym":"","url":"https://clinicaltrials.gov/study/NCT03701282","created_at":"2021-01-18T18:08:23.751Z","updated_at":"2025-02-25T15:43:14.904Z","phase":"Phase 3","brief_title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03701282","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 05/07/2028","primary_completion_date":" 05/07/2028","study_txt":" Completion: 05/07/2028","study_completion_date":" 05/07/2028","last_update_posted":"2025-02-10"},{"id":"ebb921a0-be62-4f58-b2bf-73010372d9d7","acronym":"A041702","url":"https://clinicaltrials.gov/study/NCT03737981","created_at":"2021-01-18T18:18:31.892Z","updated_at":"2025-02-25T15:34:13.549Z","phase":"Phase 3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03737981 - A041702","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 454","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-10"},{"id":"7f3be9ed-280b-4ee8-a27b-1fa29dec3944","acronym":"","url":"https://clinicaltrials.gov/study/NCT03506373","created_at":"2025-02-25T16:37:04.959Z","updated_at":"2025-02-25T16:37:04.959Z","phase":"Phase 2","brief_title":"Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia","source_id_and_acronym":"NCT03506373","lead_sponsor":"Mayo Clinic","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Ninlaro (ixazomib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 08/14/2018","start_date":" 08/14/2018","primary_txt":" Primary completion: 02/06/2023","primary_completion_date":" 02/06/2023","study_txt":" Completion: 03/11/2026","study_completion_date":" 03/11/2026","last_update_posted":"2025-02-07"},{"id":"90b17306-08d8-42c8-b26e-2dd99b9fda58","acronym":"","url":"https://clinicaltrials.gov/study/NCT01880567","created_at":"2021-01-18T08:25:52.475Z","updated_at":"2025-02-25T16:36:16.363Z","phase":"Phase 2","brief_title":"Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT01880567","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD20 • CCND1 • CCND3","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CCND1 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 07/15/2013","start_date":" 07/15/2013","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"e7cf2c99-6cfe-4015-9ca9-b9a242d379a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04739813","created_at":"2021-02-05T13:56:26.764Z","updated_at":"2025-02-25T16:38:14.078Z","phase":"Phase 1","brief_title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04739813","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2 • BCL6 • UGT1A1","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation","tags":["BCL2 • BCL6 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone • Polivy (polatuzumab vedotin-piiq)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/09/2021","start_date":" 07/09/2021","primary_txt":" Primary completion: 10/29/2025","primary_completion_date":" 10/29/2025","study_txt":" Completion: 10/29/2030","study_completion_date":" 10/29/2030","last_update_posted":"2025-02-06"},{"id":"37db9b88-cfea-407b-b290-ec67bb7844d2","acronym":"EPCORE NHL-5","url":"https://clinicaltrials.gov/study/NCT05283720","created_at":"2022-03-17T12:53:27.504Z","updated_at":"2025-02-25T16:54:10.677Z","phase":"Phase 2","brief_title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05283720 - EPCORE NHL-5","lead_sponsor":"Genmab","biomarkers":" BCL2 • CD20 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14)","tags":["BCL2 • CD20 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • prednisone • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp) • Polivy (polatuzumab vedotin-piiq) • golcadomide (CC-99282)"],"overall_status":"Recruiting","enrollment":" Enrollment 622","initiation":"Initiation: 06/14/2022","start_date":" 06/14/2022","primary_txt":" Primary completion: 11/01/2032","primary_completion_date":" 11/01/2032","study_txt":" Completion: 11/01/2032","study_completion_date":" 11/01/2032","last_update_posted":"2025-02-04"},{"id":"93cce817-ed7e-442e-95cd-47f76d702a46","acronym":"","url":"https://clinicaltrials.gov/study/NCT02159755","created_at":"2021-01-18T10:03:07.008Z","updated_at":"2025-02-25T16:51:23.872Z","phase":"Phase 1","brief_title":"Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma","source_id_and_acronym":"NCT02159755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CCND1 • CD5","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 06/25/2018","primary_completion_date":" 06/25/2018","study_txt":" Completion: 01/20/2026","study_completion_date":" 01/20/2026","last_update_posted":"2025-02-04"},{"id":"a3defc3d-df49-43a3-8fb7-35111287e449","acronym":"NCI-2016-00797","url":"https://clinicaltrials.gov/study/NCT02756897","created_at":"2021-01-18T13:30:56.475Z","updated_at":"2025-02-25T17:23:07.242Z","phase":"Phase 2","brief_title":"Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia","source_id_and_acronym":"NCT02756897 - NCI-2016-00797","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 07/07/2016","start_date":" 07/07/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-31"},{"id":"b4947302-8201-4385-90e7-1045ddc21de5","acronym":"","url":"https://clinicaltrials.gov/study/NCT03220022","created_at":"2021-01-18T15:53:27.752Z","updated_at":"2025-02-25T17:29:32.862Z","phase":"Phase 1","brief_title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","source_id_and_acronym":"NCT03220022","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Neupogen (filgrastim) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 03/16/2018","start_date":" 03/16/2018","primary_txt":" Primary completion: 06/20/2025","primary_completion_date":" 06/20/2025","study_txt":" Completion: 06/20/2025","study_completion_date":" 06/20/2025","last_update_posted":"2025-01-30"},{"id":"22cade4d-b629-4125-adda-f63eccc24007","acronym":"","url":"https://clinicaltrials.gov/study/NCT04781855","created_at":"2021-03-04T12:52:18.890Z","updated_at":"2025-02-25T17:37:01.663Z","phase":"Phase 1","brief_title":"Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation","source_id_and_acronym":"NCT04781855","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Imbruvica (ibrutinib) • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-29"},{"id":"b3cbc60c-b805-4974-b2a9-560e9eb38edd","acronym":"NCI-2018-00315","url":"https://clinicaltrials.gov/study/NCT03479268","created_at":"2021-01-18T17:08:37.744Z","updated_at":"2025-02-25T17:35:59.375Z","phase":"Phase 1","brief_title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03479268 - NCI-2018-00315","lead_sponsor":"City of Hope Medical Center","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2025-01-29"},{"id":"f788184e-3946-4215-8882-b92922df8fd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02436707","created_at":"2021-01-18T11:40:02.216Z","updated_at":"2024-07-02T16:34:26.702Z","phase":"Phase 2","brief_title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","source_id_and_acronym":"NCT02436707","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 10/27/2015","start_date":" 10/27/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-12"},{"id":"d8485b72-fd46-4a36-8dc8-65fce07dac67","acronym":"","url":"https://clinicaltrials.gov/study/NCT01841723","created_at":"2021-01-18T08:12:27.496Z","updated_at":"2024-07-02T16:34:27.123Z","phase":"Phase 2","brief_title":"Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia","source_id_and_acronym":"NCT01841723","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 04/30/2013","start_date":" 04/30/2013","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-11"},{"id":"8e23dfed-66db-4dea-b013-38aff34edc35","acronym":"NCI-2015-00960","url":"https://clinicaltrials.gov/study/NCT02427620","created_at":"2021-01-17T17:51:13.234Z","updated_at":"2024-07-02T16:34:36.739Z","phase":"Phase 2","brief_title":"Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma","source_id_and_acronym":"NCT02427620 - NCI-2015-00960","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • MYC • CD20","pipe":" | ","alterations":" TP53 mutation • CD20 positive","tags":["TP53 • MYC • CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • daunorubicin • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 131","initiation":"Initiation: 06/03/2015","start_date":" 06/03/2015","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-06-10"}]